GlassScriptPhysician profile
Paul R Moncla
NPI 1477533065
$2,171.76
in general payments reported to CMS, 2019-2025
24 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $55.01 · 2021: $209 · 2022: $351 · 2023: $454 · 2024: $363 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $293.69 | 2022-2025 | Injectafer |
| Hologic Sales and Service, LLC | $274.72 | 2019-2023 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Abbvie INC. | $228.80 | 2019-2023 | |
| Minerva Surgical, INC | $212.22 | 2019-2024 | |
| Organon LLC | $201.18 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $166.80 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $143.68 | 2023-2025 | Myfembree, Gemtesa |
| Momentis Surgical INC. | $107.00 | 2022 | |
| Novo Nordisk INC | $101.39 | 2021-2025 | Wegovy |
| Exeltis, USA INC. | $74.80 | 2021-2025 | Slynd |
| Urovant Sciences INC | $74.50 | 2021 | |
| Lilly USA, LLC | $55.28 | 2024-2025 | Zepbound |
| Pfizer INC. | $50.09 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.81 | 2024 | |
| Aspira Women'S Health INC | $23.95 | 2024 | Ova1 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $23.37 | 2022 | |
| Coopersurgical, INC. | $22.62 | 2019-2020 | |
| Medtronic, INC. | $17.60 | 2024 | Interstim |
| Meditrina | $15.35 | 2025 | |
| Covidien LP | $14.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.11 | 2023 | Seglentis |
| Avion Pharmaceuticals | $13.78 | 2021 | |
| Glaxosmithkline, LLC. | $11.72 | 2019 | |
| Alydia Health | $4.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Moncla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.